AWH Aspira Womens Health Inc

Aspira Women’s Health, Inc. to Report Third Quarter 2020 Financial Results on November 12th

Aspira Women’s Health, Inc. to Report Third Quarter 2020 Financial Results on November 12th

AUSTIN, Texas, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced it will report financial results for the third quarter ended September 30, 2020 on Thursday, November 12, 2020 after the market close, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.

Thursday, November 12th @ 4:30pm ET
Domestic:877-407-4018
International:201-689-8471
Conference ID: 13712253
Webcast:

About Aspira Women’s Health Inc.

Aspira Women’s Health, Inc. (formerly known as, Vermillion inc., Nasdaq: VRML) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women.  ASPIRA is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1® and OVERA® to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX™ testing offers both targeted and comprehensive genetic testing options with a gynecologic focus.  With over 10 years of expertise in ovarian cancer risk assessment, ASPIRA is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVANEX™ and EndoCheck™. Visit our website for more information at .

Investor Relations Contact:

Ashley R. Robinson

LifeSci Advisors, LLC

Tel 617-430-7577

EN
04/11/2020

Underlying

AWHAspira Womens Health Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aspira Womens Health Inc

 PRESS RELEASE
Free
AWH Aspira Womens H...

Aspira Women’s Health Announces Appointment of Dr. Sandra Milligan as ...

Aspira Women’s Health Announces Appointment of Dr. Sandra Milligan as Interim CEO CEO Nicole Sandford will step down for personal reasons and will remain as a consultant to ensure a seamless transition AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira...

December 16, 2024 1 EN
 PRESS RELEASE
Free
AWH Aspira Womens H...

Aspira Women’s Health Successfully Reaches the First Milestone of the ...

Aspira Women’s Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award The Company received the first $2 million from the ARPA-H Sprint for Women’s Health Award AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the first development milestone of its  (ARPA-H) award. As a result, Aspira has received a $2 million cash payment under the terms of the related a...

December 3, 2024 1 EN
 PRESS RELEASE
Free
AWH Aspira Womens H...

Aspira Women’s Health Reports Selected Third Quarter 2024 Financial Re...

Aspira Women’s Health Reports Selected Third Quarter 2024 Financial Results Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic...

November 14, 2024 1 EN
 PRESS RELEASE
Free
AWH Aspira Womens H...

Aspira Women’s Health Expands Co-Marketing and Distribution Collaborat...

Aspira Women’s Health Expands Co-Marketing and Distribution Collaboration with BioReference® to Include OvaWatch® BioReference team is now able to provide the entire OvaSuite portfolio to healthcare providers in New York and New Jersey AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the expansion of its co-marketing and distribution collaboration with BioReference Health, LLC (“BioReference”), a wholly-own...

November 7, 2024 1 EN
 PRESS RELEASE
Free
AWH Aspira Womens H...

Aspira Women’s Health to Announce Third Quarter Earnings Results and H...

Aspira Women’s Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024 Management to Announce Earnings Results and hold a call at 8:30 am ET AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management w...

November 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch